Sium Abraham Fessehaye, Abdu Amani Nureddin, Beyene Zerihun
Department of Obstetrics and Gynecology, St. Paul's Hospital Millennium Medical College (SPHMMC), Addis Ababa, Ethiopia.
Contracept X. 2024 Aug 8;6:100110. doi: 10.1016/j.conx.2024.100110. eCollection 2024.
To compare the effectiveness and safety of dilation and evacuation (D&E) to that of medication abortion at 15-24 weeks in a low-middle income country.
We conducted a retrospective cohort on effectiveness and safety of D&E vs medication abortion at 15-24 weeks in an Ethiopian setting over a year (January 1-December 31, 2023). We looked at success (need for additional procedure) of both abortion procedures and their complication rates. Hemorrhage, infection, uterine perforation/rupture, and cervical tear were the complications we compared between the groups (D&E group vs medication abortion group). -value less than 0.05 and Adjusted odds ratio (AOR) with 95% CI were used to present results significance.
A total of 225 abortion cases (162 medication abortion cases and 63 D&E cases) at gestational age of 15-24 weeks were included in the final analysis. The mean gestational age was 18 ± 2.8 weeks in the D&E group compared to 21 ± 3 weeks in the medication abortion group (-value < 0.001). The overall procedure effectiveness between the abortion procedures was similar (95.2% vs 96.9% in the D&E group and medication abortion groups, -value = 0.542). D&E (AOR = 2.92 [95% CI = 0.62-13.69]) was not associated with increased overall complications compared to medication abortion, after controlling for parity, gestational age, and history of prior uterine scar.
We found both abortion methods (D&E and medication abortion) are effective with comparable complication rates.
D&E and medication abortion are safe and effective methods of abortion for gestations up to 24 weeks even in a low-middle income country (LMIC) setting; as such, greater resources are needed to ensure to increase availability of D&E in order for women to have a choice in their treatment options.
比较在中低收入国家,孕15 - 24周时扩张刮宫术(D&E)与药物流产的有效性和安全性。
我们在埃塞俄比亚进行了一项回顾性队列研究,观察2023年1月1日至12月31日这一年中,孕15 - 24周时D&E与药物流产的有效性和安全性。我们考察了两种流产手术的成功率(是否需要额外手术)及其并发症发生率。我们比较了两组(D&E组与药物流产组)之间的出血、感染、子宫穿孔/破裂和宫颈撕裂等并发症情况。结果的显著性采用p值小于0.05以及95%置信区间的调整比值比(AOR)来呈现。
最终分析纳入了225例孕15 - 24周的流产病例(162例药物流产病例和63例D&E病例)。D&E组的平均孕周为18±2.8周,而药物流产组为21±3周(p值<0.001)。两种流产手术的总体手术有效性相似(D&E组和药物流产组分别为95.2%和96.9%,p值 = 0.542)。在控制了产次、孕周和既往子宫瘢痕史后,与药物流产相比,D&E(AOR = 2.92 [95% CI = 0.62 - 13.69])与总体并发症增加无关。
我们发现两种流产方法(D&E和药物流产)都有效,并发症发生率相当。
即使在中低收入国家(LMIC)环境下,D&E和药物流产对于孕24周以内的妊娠都是安全有效的流产方法;因此,需要更多资源来确保增加D&E的可及性,以便女性能够在治疗选择上有更多选择。